Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 13Unknown 6Withdrawn 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6CNS 4Other solid neoplasm 3Head & Neck 3Dermatologic 3Breast 3Sarcoma 2Other hematologic neoplasm 2Other 2Gynecologic 2Gastrointestinal 2Thoracic 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Paclitaxel 79Carboplatin 66pembrolizumab 61Bevacizumab 56Cisplatin 48Specimen Handling 29Drug Therapy 26Blood Specimen Collection 24Cyclophosphamide 20olaparib 19Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14fludarabine 14Brachytherapy 14Radiotherapy 13abemaciclib 12Topotecan 11Nivolumab 11Injections 11Doxorubicin 11lenvatinib 10Fluorouracil 10atezolizumab 9Surveys and Questionnaires 9Standard of Care 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Metformin × Gynecologic × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡